Expression of Endocan in Tissue Samples from Prostate Adenocarcinoma and Prostate Hyperplasia: A comparative retrospective study
Urology Journal,
Vol. 18 No. 05 (2021),
7 Aban 2021
,
Page 530-536
https://doi.org/10.22037/uj.v18i05.6544
Abstract
Purpose: In this study, we aimed to determine whether there is a significant difference in endocan expression levels between prostate adenocarcinoma and prostate hyperplasia tissues by using an immunohistochemical method.
Materials and Methods: All of 51 patients, who were getting treatment for the last 5 years, participated in the study. 31 of 51 patients underwent transrectal sonography (TRUSG) -assisted prostate biopsy because of prostate adenocarcinoma as diagnosed with elevated PSA levels and histopathological examination. The remaining 20 patients comprised the control group. The control group included patients with benign prostate hyperplasia based on pathological examination.
Results: It was found that there was strong positive epithelial staining in 74.2% of patients with prostate cancer while in 5% of controls, indicating a statistically significant difference (P < .001). It was also found that the rate of strong positive endothelial staining was 77.4% in the patient group whereas 5% in the control group (P < .001). Also, the rate of strong positive stromal staining was 64.5% in the patient group while 5% in the control group (P < .001).
Conclusion: We found that tissue endocan expression level was statistically significantly higher in patients with prostate cancer compared to those with benign prostate hyperplasia by using an immunohistochemical method.
- Benign prostate hyperplasia; endocan; expression; immunohistochemistry; prostate adenocarcinoma.
How to Cite
References
2. Rawla P. Epidemiology of Prostate Cancer. World j Oncol. 2019;10(2):63-89.
3. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581-592.
4. Hodges KB, Bachert E, Cheng L. Prostate Cancer Biomarkers: Current Status. Crit Rev Oncog. 2017; 22: 253-269.
5. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit. Rev. Clin.Lab. Sci. 1998; 35:275-368.
6. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027-35.
7. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J. Urol. 2017; 197:200-207.
8. Delehedde M, Devenyns L, Maurage CA, Vivès RR. Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol. 2013;2013:705027. Epub 2013 Mar 28.
9. Lassalle P, Molet S, Janin A et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271:20458-64.
10. Sarrazin S, Adam E, Lyon M et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765:25-37.
11. Kali A and Rathan Shetty KS. Endocan: A novel circulating proteoglycan. Indian J Pharmacol. 2014;46:579-583.
12. Roudnicky F, Poyet C, Wild P et al. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res. 2013;73:1097-106.
13. Scherpereel A, Gentina T, Grigoriu B et al. “Overexpression of endocan induces tumor formation. Cancer Res. 2003;63:6084-9.
14. Huang G-W, Tao Y-M and Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig.Dis. Sci. 2009;54:389-394.
15. Maurage C-A, Adam E, Min´eo J-F et al. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol. 2009; 68: 633-641.
16. Matano F, Yoshida D, Ishii Y, Tahara S, Teramoto A and Morita A. Endocan,a new invasion and angiogenesis marker of pituitary adenomas. J Neurooncol. 2014;117:485-491.
17. Scherpereel A, Depontieu F, Grigoriuetal B et al. Endocan,a new endothelial marker in human sepsis. Crit Care Med. 2006;34:532-37.
18. Kiliç R, Kurt A, Tad M, Taşdemir S. Endocan Overexpression in Pterygium. Cornea. 2017; 36: 696-99.
19. Laloglu E, Aksoy H, Aksoy Y, Ozkaya F, Akcay F. The determination of serum and urinary endocan concentrations in patients with bladder cancer. Ann Clin Biochem. 2016;53: 647-653.
20. Leroy X, Aubert S, Zini L et al. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology. 2010; 56:180-7.
21. Arslan B, Onuk Ö, Hazar İ et al. Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy. Tumori. 2017;103:204-208.
22. Akarsu M, Atalay HA, Canat L et al. Endocan is markedly overexpressed in severe erectile dysfunction. Andrologia. 2018 Apr;50(3). Epub 2017 Oct 23.
23. Asgari M, Eftekhar E, Abolhasani M, Shahrokh H. Endothelin-1 Expression in Prostate Needle Biopsy Specimens Correlated With Aggressiveness of Prostatic Cancer. Iran J Pathol. 2017;12:171-176.
24. Cox LA, Van Eijk LT, Ramakers BP et al. Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock. 2015; 43:322-326.
25. Nordby Y, Andersen S, Richardsen E et al. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy. The Prostate. 2015;75:1682-1693.
26. Lai CY, Chen CM, Hsu WH, Hsieh YH, Liu CJ. Overexpression of Endothelial Cell-Specific Molecule 1 Correlates with Gleason Score and Expression of Androgen Receptor in Prostate Carcinoma. Int. J. Med. Sci. 2017;14:1263-1267.
- Abstract Viewed: 311 times
- 6544/pdf Downloaded: 175 times